EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Caroline Even, Kevin J Harrington, Erminia Massarelli, Simon Laban, Jérôme Fayette, Marc Oliva, Marielle Klein Hesselink, Sonja Visscher, Matthew G Fury, Anna-Sophia Wiekmeijer, Lisa Licitra, Bohuslav Melichar und 9 weitere

Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012555

DOI: 10.1136/jitc-2025-012555 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.09.2025. Verfasst von Caroline Even und 20 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Oncology, Gustave Roussy Institute, Villejuif, Île-de-France, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Human papillomavirus 16, Head and Neck Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ISA Pharmaceuticals, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peltopepimut-S is a therapeutic vaccine, which induces specific expansion of both CD4+helper and CD8+cytotoxic T-cells against human papillomavirus type 16 (HPV16) E6/E7 oncoproteins. Patients and methods In a randomized phase 2 trial, we evaluated the efficacy and safety of peltopepimut-S plus cemiplimab compared with cemiplimab alone as first-line or second-line therapy in recurrent/metastatic HPV16-positive head and neck cancer. The primary efficacy endpoint was the objective response rate (ORR) by an independent review (Response Evaluation Criteria in Solid Tumors version 1.1, RECIST v1.1), while the primary safety endpoint was frequency and severity of adverse events. Secondary endpoints included progression-free survival (PFS) and overall survival (OS).

Results

Overall, 198 anti-programmed cell death protein-1 therapy-naïve patients with confirmed HPV16-positive recurrent/metastatic oropharyngeal cancer were randomized to receive cemiplimab plus peltopepimut-S (n=100) or placebo (n=99). The trial did not meet its primary objective (ORR, 25.3% in peltopepimut-S arm vs 22.9% in placebo arm; p=0.735). The median OS (mOS) and PFS in the placebo arm were unexpectedly longer than in the peltopepimut-S arm (26.9 vs 15.8 months) and (20.3 vs 5.5 months), respectively. In predefined exploratory analyses this was associated with an excess death rate from progressive disease in patients with pre-treatment programmed death-ligand 1 (PD-L1) combined positive score (CPS)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHuman papillomavirus 16Head and Neck NeoplasmsPapillomavirus InfectionsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultTreatment Outcome

Stichwörter der Autor:innen

Combination therapyHead and Neck CancerImmune Checkpoint InhibitorVaccineViral-specific T cells

Substanzen

Antibodies, Monoclonal, Humanizedcemiplimab

Autor:innen und Institutionen

  • Head and Neck Oncology, Gustave Roussy Institute, Villejuif, Île-de-France, France.
  • Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
  • Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Otorhinolaryngology and Head and Neck Surgery, Universitatsklinikum Ulm, Ulm, Germany.
  • Centre Léon Bérard, Lyon, France.
  • Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain.

Förderung

  • ISA Pharmaceuticals
  • Regeneron Pharmaceuticals

Zitieren

APA

Even, C., Harrington, K. J., Massarelli, E., Laban, S., Fayette, J., Oliva, M., Klein Hesselink, M., Visscher, S., Fury, M. G., Wiekmeijer, A. S., Licitra, L., Melichar, B., Devriese, L. A., Braña, I., Jankowska, P., Posner, M., Glisson, B., Kong, A., Hooftman, L., …, & Ferrarotto, R. (2025). Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. Journal for ImmunoTherapy of Cancer, 13(9), e012555. https://doi.org/10.1136/jitc-2025-012555

Vancouver

Even C, Harrington KJ, Massarelli E, Laban S, Fayette J, Oliva M, et al. Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. Journal for ImmunoTherapy of Cancer. 2025;13(9):e012555. doi:10.1136/jitc-2025-012555

BibTeX
@article{Even2025,
  author = {Even, Caroline and Harrington, Kevin J and Massarelli, Erminia and Laban, Simon and Fayette, Jérôme and Oliva, Marc and Klein Hesselink, Marielle and Visscher, Sonja and Fury, Matthew G and Wiekmeijer, Anna-Sophia and Licitra, Lisa and Melichar, Bohuslav and Devriese, Lot A and Braña, Irene and Jankowska, Petra and Posner, Marshall and Glisson, Bonnie and Kong, Anthony and Hooftman, Leon and Melief, Cornelis J M and Ferrarotto, Renata},
  title = {Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {9},
  pages = {e012555},
  doi = {10.1136/jitc-2025-012555}
}
Kostenlos starten →